Adjuvant Treatment Approaches for Renal Cell Carcinoma: Insights from Historical Challenges and Emerging Possibilities with Immune Checkpoint Inhibitors - Top-Institutions - MDSpire

Adjuvant Treatment Approaches for Renal Cell Carcinoma: Insights from Historical Challenges and Emerging Possibilities with Immune Checkpoint Inhibitors

  • By

  • Liu, Zengguang

  • Cong, Xiaofeng

  • Liu, Ziyi

  • Yin, Jiaxin

  • Chen, Chen

  • Liu, Ziling

  • April 7, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Immunotherapy Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Immuno-oncology
    • Clinical Trials

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Immunotherapy

  • #4

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Medical Oncology
    • Translational Oncology
    • Immunotherapy

  • #5

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Immunotherapy Research

Original Source(s)

Adjuvant Treatment Approaches for Renal Cell Carcinoma: Insights from Historical Challenges and Emerging Possibilities with Immune Checkpoint Inhibitors

  • by Liu, Zengguang , Cong, Xiaofeng , Liu, Ziyi , Yin, Jiaxin , Chen, Chen , Liu, Ziling

  • April 7, 2026

Related Content

Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations

Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation

Non-bacterial cystitis following treatment with toripalimab for alpha-fetoprotein-producing gastric adenocarcinoma: a case report